{"product_id":"pypd-pestle-analysis","title":"(PYPD) PolyPid Ltd. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis PolyPid Ltd. PESTLE Analysis helps you quickly grasp the political, economic, social, technological, legal, and environmental forces shaping the company and its risks\/opportunities; the page shows a real preview of the report so you can judge style and depth before buying — purchase the full version to receive the complete, ready-to-use company-specific analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael headquarters since 2008\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s Petah Tikva base ties it to Israeli public policy, healthcare spending, and capital-market rules. Israel still ranks among the top R\u0026amp;D spenders, with research investment above 6% of GDP, which can support local talent and life-science incentives.\u003c\/p\u003e\n\u003cp\u003eThat local setup helps clinical access and supplier oversight, but it also leaves PolyPid Ltd. exposed to regional geopolitical risk. For trials, supply continuity, and investor sentiment, even short disruptions in Israel can move timelines and raise costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III trial depends on health-authority approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.'s D-PLEX100 is in Phase III, so it still needs approvals from ethics boards, regulators, and trial sites before each major step. Any protocol change, site delay, or government review can push timelines back and slow the path to commercialization. For a late-stage drug, steady support for healthcare innovation matters because even short approval delays can affect market entry and financing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSSI prevention targets public hospital budgets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgical site infections remain a budget strain for public hospitals: they drive longer stays, readmissions, and extra antibiotic use. WHO says SSIs can affect up to 11% of surgical patients in lower-income settings, so prevention gets priority when ministries weigh cost savings. PolyPid Ltd’s lead product can gain traction if public systems see fewer avoidable complications and lower total treatment costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUS and EU market entry needs regulator coordination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd.'s growth outside Israel depends on FDA and EMA approval, because the US spent $4.9 trillion on health care in 2023 and the EU covers 27 tightly regulated markets.\u003c\/p\u003e\n\u003cp\u003ePolitical ties, trade rules, and cross-border supply controls can still slow labeling, import, and reimbursement, so regulator coordination is a real revenue issue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA and EMA gate market entry.\u003c\/li\u003e\n\u003cli\u003eUS-EU rules affect launch timing.\u003c\/li\u003e\n\u003cli\u003eAccess decides sales scale.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeopolitical risk can affect supply and trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeopolitical shocks can hit PolyPid Ltd’s trials and manufacturing fast: conflict, airline limits, and port delays can slow patient visits, site monitoring, and study-supply delivery. In 2025, Red Sea shipping risk still pushed rerouting costs higher, adding days to global transit times and pressuring vendors. For a single lead asset, even a short delay can distort enrollment and trial timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eConflict can delay site access and monitoring.\u003c\/li\u003e\n\u003cli\u003eShipping breaks can slow study materials.\u003c\/li\u003e\n\u003cli\u003eGlobal trials need stable vendors and logistics.\u003c\/li\u003e\n\u003cli\u003eSingle-asset risk makes delays more material.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIsrael's R\u0026amp;D Edge Meets PolyPid's Geopolitical Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. benefits from Israel’s strong R\u0026amp;D policy support, but its Petah Tikva base also ties it to Israeli budget, healthcare, and security decisions. With Israel’s R\u0026amp;D spend above 6% of GDP and D-PLEX100 still needing FDA and EMA approvals, political support for life sciences can speed progress, while any conflict, port delay, or site review can slow trials and raise costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;6% of GDP\u003c\/td\u003e\n\u003ctd\u003eSupports biotech ecosystem\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket access\u003c\/td\u003e\n\u003ctd\u003eFDA, EMA\u003c\/td\u003e\n\u003ctd\u003eGates launch timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGeopolitics\u003c\/td\u003e\n\u003ctd\u003eTrial and shipping risk\u003c\/td\u003e\n\u003ctd\u003eCan delay supply and enrollment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes how Political, Economic, Social, Technological, Environmental, and Legal forces shape PolyPid Ltd.’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, easy-to-scan PESTLE summary of PolyPid Ltd. that quickly eases external risk and market positioning analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography linking each major PolyPid claim to primary industry reports, clinical data, and government sources to speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage biotech funding needs are high\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase III biotech work is expensive, often costing tens of millions of dollars for trial runs, scale-up manufacturing, regulatory filings, and launch prep. For PolyPid Ltd., access to capital is a core risk because late-stage funding was still selective in 2025, even as biotech financing improved from the 2023 slump. Investor appetite now directly affects how fast PolyPid Ltd. can finish development and reach market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eD-PLEX100 addresses SSI-related cost burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgical site infections add avoidable cost through longer stays, readmissions, and extra antibiotics; CDC data still puts SSI impact at billions of dollars each year in the U.S. For PolyPid Ltd, D-PLEX100 is economically attractive only if it cuts complications enough to offset pricing, and that cost-offset case is central to payer reimbursement and hospital adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2 surgical markets: sternal and abdominal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid is testing D-PLEX100 in both sternal and abdominal surgery, which widens the addressable market and lowers dependence on one procedure type. The two settings can also face different buyer behavior, with hospital procurement and reimbursement rules shaping uptake in different ways. That matters because sternal and abdominal procedures can follow separate economic paths, so success in both could broaden future revenue options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRevenue depends on reimbursement after approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEven after approval, PolyPid Ltd. can still face slow hospital uptake because reimbursement and formulary access often decide who gets paid. In the US, most inpatient drugs are folded into DRG payments, so payers may want proof of lower total cost, not just clinical benefit; ICER often benchmarks value at about $100,000 to $150,000 per QALY. That makes health-economics data as important as trial results.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReimbursement can delay adoption.\u003c\/li\u003e\n\u003cli\u003ePayers want cost-effectiveness evidence.\u003c\/li\u003e\n\u003cli\u003eValue data can speed access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFX exposure spans shekel, dollar and euro\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. is Israel-based but aims to sell globally, so its cash flows can swing with the shekel, US dollar, and euro. That matters because trial spending, payroll, and local overhead are often in shekels, while commercialization and partner deals may be in dollars or euros. FX moves can lift or cut reported revenue, opex, and margin.\u003c\/p\u003e\n\u003cp\u003eFor a small biotech, even modest currency moves can be material versus 2025-2026 cash burn and trial budgets. Currency hedging and matching costs to the same currency are important controls.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShekel costs, dollar funding, euro sales\u003c\/li\u003e\n\u003cli\u003eFX hits trials, opex, reported results\u003c\/li\u003e\n\u003cli\u003eHedging can reduce cash-flow swings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s Big Test: Prove Value, Not Just Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic risk for PolyPid Ltd. is driven by late-stage trial spend, payer proof, and FX swings. SSI care still costs U.S. hospitals billions yearly, so D-PLEX100 must show lower total cost, not just efficacy. Inpatient reimbursement can slow uptake, and value proof near $100,000-$150,000 per QALY matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI burden\u003c\/td\u003e\n\u003ctd\u003eBillions yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue benchmark\u003c\/td\u003e\n\u003ctd\u003e$100k-$150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech funding\u003c\/td\u003e\n\u003ctd\u003eSelective in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePolyPid Ltd. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PolyPid Ltd. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSSI prevention responds to patient safety demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients and clinicians now expect surgery to do more than fix the main problem: it should also avoid infection. SSIs are among the most visible hospital-acquired infections, and they can add about 7 to 10 extra hospital days and lift treatment costs sharply. A prevention product like PolyPid Ltd.’s fits that safety demand, which can support faster acceptance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging populations raise surgery volumes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOlder populations need more procedures and face more complications, so SSI prevention matters more. The UN says people aged 65+ numbered about 761 million in 2021 and are set to reach 1 in 6 people by 2030, which should lift surgery volumes and widen the use case for PolyPid Ltd. D-PLEX100. More surgeries also support the broader SSI-prevention market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital-acquired infection awareness is high\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAwareness of hospital-acquired infections stays high, and the CDC says about 1 in 31 U.S. hospital patients has at least one HAI on any day. Public concern often jumps after severe outbreak reports or poor care scores, so products that reduce infection risk can get faster attention from patients, providers, and regulators. That social pressure can also speed adoption and support pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSurgeon adoption depends on clinical trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSurgeons adopt new products only when clinical trust is clear, because operating-room use leaves no room for guesswork. For surgical site infection, a common benchmark risk is 2% to 5% in U.S. inpatient surgery, so products must show strong efficacy, simple use, and steady results before they enter routine practice.\u003c\/p\u003e\n\u003cp\u003eTrust usually comes from peer-reviewed data plus real-world outcomes, not marketing. For PolyPid Ltd., that means surgeons will want proof that each use delivers the same result in live cases, with low added workflow burden and no disruption to standard surgery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrust drives surgeon adoption\u003c\/li\u003e\n\u003cli\u003ePeer-reviewed data matters most\u003c\/li\u003e\n\u003cli\u003eEase of use speeds uptake\u003c\/li\u003e\n\u003cli\u003eConsistent outcomes support routine use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMinimally disruptive infection control is preferred\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHealthcare teams favor infection control that fits standard operating room flow. If D-PLEX100 adds steps, adoption can slow; in busy hospitals, even small workflow friction matters. Surgical site infections still affect about 2% to 5% of clean surgeries, so a product must show clear value without disrupting staff time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBest fit: low-friction OR use\u003c\/li\u003e\n\u003cli\u003eHigh value: fewer workflow steps\u003c\/li\u003e\n\u003cli\u003eRisk: slower uptake if complex\u003c\/li\u003e\n\u003cli\u003eNeed: proof in busy settings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid Gains on Proven Infection Reduction, Not Promises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical trust and surgeon habit drive PolyPid Ltd. adoption: in the U.S., SSI risk is still about 2% to 5% in clean surgery, so teams want proof, not claims. Patients also expect fewer infections, since HAIs hit about 1 in 31 U.S. hospital patients on any day.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSSI risk\u003c\/td\u003e\n\u003ctd\u003e2% to 5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHAI burden\u003c\/td\u003e\n\u003ctd\u003e1 in 31 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOlder adults\u003c\/td\u003e\n\u003ctd\u003e761M age 65+ in 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePLEX polymer-lipid encapsulation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePLEX is PolyPid Ltd.’s proprietary polymer-lipid encapsulation matrix, and it sits at the center of the Company’s drug pipeline. A single platform can support multiple future candidates, which makes it a key technological asset and a source of differentiation. In 2025, PolyPid remained a development-stage Company, so PLEX’s value is tied to pipeline expansion and clinical execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase III candidate D-PLEX100\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eD-PLEX100 is PolyPid Ltd.’s lead candidate and is in Phase III, so the technology has moved past early proof-of-concept and into late-stage validation. At this stage, success depends on consistent efficacy, tight manufacturing quality, and clean trial data, which makes the program highly visible to investors and regulators. A Phase III asset also carries the highest technical and execution risk before approval.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLocal, sustained delivery around surgery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.’s D-PLEX100 is built to release drug locally at the surgical site, so treatment is concentrated where infection risk is highest. Sustained release matters because the first 7-14 days after surgery are the key window for many surgical-site infections, and keeping coverage in place can be more useful than a single bolus dose. This local, long-acting design is a core technical edge to judge against standard IV prophylaxis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and commercialization capabilities required\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. is moving from Phase 3 development to commercial readiness, so manufacturing now has to prove reproducibility, sterile fill-finish, and tight quality control. If trials succeed, the same process must support steady commercial supply without batch drift. One lab win is not enough; scale-up risk can still break launch plans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScale sterile production before approval.\u003c\/li\u003e\n\u003cli\u003eLock in batch-to-batch reproducibility.\u003c\/li\u003e\n\u003cli\u003ePrepare packaging for commercial release.\u003c\/li\u003e\n\u003cli\u003eValidate supply against launch demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2 SSI indications in late-stage testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd.’s D-PLEX100 is in late-stage testing for two SSI settings: sternal and abdominal surgery. That split raises validation work because each site has different wound conditions, infection risk, and trial endpoints. The company reported a cash balance of about $18.6 million as of Q1 2025, so the dual-path program adds execution pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo indications mean more clinical proof.\u003c\/li\u003e\n\u003cli\u003eDifferent surgery types raise trial complexity.\u003c\/li\u003e\n\u003cli\u003eLate-stage testing needs separate endpoint checks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s PLEX Platform Faces a Crucial 2025 Execution Test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.'s technological edge is PLEX, a local, sustained-release matrix that supports D-PLEX100 and can be reused across candidates. In 2025, the main tech test was execution: Phase III data, sterile scale-up, and batch consistency had to hold together. Cash was about $18.6 million in Q1 2025, so development speed matters.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eD-PLEX100 stage\u003c\/td\u003e\n\u003ctd\u003ePhase III\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 cash\u003c\/td\u003e\n\u003ctd\u003e$18.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey tech risk\u003c\/td\u003e\n\u003ctd\u003eScale-up and reproducibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trials require FDA and EMA compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd.'s late-stage trials must meet FDA and EMA rules on protocol design, safety monitoring, and data integrity. In the U.S., serious adverse events can trigger 15-day FDA reporting, so weak controls can delay or block review. \u003c\/p\u003e\n\u003cp\u003eWith two major regulators to satisfy, any future approval will hinge on clean, auditable trial data and compliant reporting. For a biopharma company, regulatory compliance is a core legal risk, not a back-office task.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP protection is central to PLEX\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePLEX depends on strong patent protection, because patents can block copycats for up to 20 years from filing. That matters for PolyPid Ltd. because exclusivity supports pricing power and protects the value of its drug-delivery platform. If those rights weaken or expire, rivals can copy core elements faster and pressure margins. For a platform like PLEX, legal protection is a core part of long-term value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGCP and pharmacovigilance obligations apply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd’s clinical programs must follow Good Clinical Practice, with ongoing safety review and strict adverse-event reporting. In the U.S., serious unexpected adverse events are typically reported within 15 days, and life-threatening cases within 7 days. These duties continue after approval, so any gap in records or reporting can delay trials, trigger FDA action, or derail the program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct labeling must support SSI claims\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf PolyPid Ltd. wins approval, the label must stay tightly aligned with trial data, especially on surgical site infection prevention. Regulators will check that every claim is backed by evidence and that wording does not overstate benefit. This matters because label scope can shape uptake, pricing power, and peak sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClaims must match trial results\u003c\/li\u003e\n\u003cli\u003eSSI wording faces close review\u003c\/li\u003e\n\u003cli\u003eOverstatement can delay approval\u003c\/li\u003e\n\u003cli\u003eLabel scope can limit revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData privacy rules govern patient records\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical studies at PolyPid Ltd. can handle sensitive patient data across sites, so privacy law and consent rules are central to compliance. Under GDPR, fines can reach €20 million or 4% of global annual turnover, and cross-border trials add transfer and local filing risk. Strong data governance, audit trails, and clear consent records help protect trust and reduce legal exposure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-site trials raise privacy risk.\u003c\/li\u003e\n\u003cli\u003eCross-border transfers need extra controls.\u003c\/li\u003e\n\u003cli\u003eConsent records must stay audit-ready.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid’s Legal Risks Could Delay Approval and Limit Pricing Power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. faces tight legal risk from FDA, EMA, GCP, and privacy rules, so any gap in trial conduct, safety reporting, or data integrity can delay approval. Its patent cover and label wording also matter, because they protect pricing power and limit how far claims can go.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal item\u003c\/th\u003e\n\u003cth\u003eKey risk\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA safety reports\u003c\/td\u003e\n\u003ctd\u003eLate filing can stall review\u003c\/td\u003e\n\u003ctd\u003e7-15 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatent term\u003c\/td\u003e\n\u003ctd\u003eCopycat risk on expiry\u003c\/td\u003e\n\u003ctd\u003eUp to 20 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR fines\u003c\/td\u003e\n\u003ctd\u003ePrivacy breach exposure\u003c\/td\u003e\n\u003ctd\u003e€20m or 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use surgical care creates medical waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOperating rooms create a large waste stream: U.S. hospitals generate about 5.9 million tons of waste a year, and surgery is a major source of single-use plastics and contaminated disposables.\u003c\/p\u003e\n\u003cp\u003eFor PolyPid Ltd., any surgical product must fit strict hospital waste rules, because packaging, applicators, and used materials all add to landfill or regulated medical-waste load.\u003c\/p\u003e\n\u003cp\u003eWaste reduction is now part of procurement talks, since healthcare drives about 4.4% of global net emissions and buyers increasingly favor lower-waste products.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfection prevention can reduce resource use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf D-PLEX100 cuts surgical site infections, it can reduce repeat procedures and longer stays, which lowers use of beds, staff time, drugs, and OR capacity. In the U.S., surgical site infections still affect about 2% to 5% of inpatient surgeries, so even small gains can free meaningful hospital resources. That makes clinical benefit and environmental efficiency move in the same direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma manufacturing must control emissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs PolyPid Ltd scales biopharma output toward commercialization, it must control air emissions, water use, and process waste alongside GMP quality. EU CSRD reporting now reaches about 50,000 companies from 2025, so environmental data collection is becoming a real operating cost. Higher batch volumes also mean more solvent, energy, and wastewater loads, raising compliance risk if plant controls lag.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSterile packaging adds material intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSterile packaging raises PolyPid Ltd.'s material intensity because medical products often need multilayer wraps, barrier films, and controlled storage, which increases plastic and paper use plus disposal load. Hospitals and distributors are tightening packaging-scrutiny, and in the EU, 2025 rules under the Packaging and Packaging Waste Regulation push recyclability and waste cuts, so packaging footprint can affect purchasing preferences over time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore layers mean more material use.\u003c\/li\u003e\n\u003cli\u003eWaste rules are getting stricter.\u003c\/li\u003e\n\u003cli\u003ePackaging can sway procurement choices.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chains face waste and disposal rules\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolyPid Ltd. faces higher logistics cost because medical supply chains must track controlled transport, expired stock, and hazardous waste rules; WHO says about 15% of healthcare waste is infectious or hazardous. For a surgical product, end-to-end disposal planning matters, not just delivery.\u003c\/p\u003e\n\u003cp\u003eGlobal distribution also adds country-by-country compliance, so packaging, returns, and incineration or treatment routes must be built into the network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15% hazardous healthcare waste\u003c\/li\u003e\n\u003cli\u003eEnd-to-end waste control is critical\u003c\/li\u003e\n\u003cli\u003eGlobal rules raise logistics cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolyPid Faces Mounting Pressure to Cut Waste and Emissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolyPid Ltd. faces rising pressure on waste, packaging, and emissions as hospitals cut landfill and medical-waste loads. U.S. hospitals generate about 5.9 million tons of waste a year, and healthcare drives about 4.4% of global net emissions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare waste\u003c\/td\u003e\n\u003ctd\u003e5.9M tons\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal emissions\u003c\/td\u003e\n\u003ctd\u003e4.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous waste\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234838421769,"sku":"pypd-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pypd-pestle-analysis.webp?v=1785729445","url":"https:\/\/dcfanalyst.com\/products\/pypd-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}